Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade

International Journal of Molecular Sciences
Julie VackovaMichal Smahel

Abstract

Programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) blockade is a promising therapy for various cancer types, but most patients are still resistant. Therefore, a larger number of predictive biomarkers is necessary. In this study, we assessed whether a loss-of-function mutation of the interferon (IFN)-γ receptor 1 (IFNGR1) in tumor cells can interfere with anti-PD-L1 therapy. For this purpose, we used the mouse oncogenic TC-1 cell line expressing PD-L1 and major histocompatibility complex class I (MHC-I) molecules and its TC-1/A9 clone with reversibly downregulated PD-L1 and MHC-I expression. Using the CRISPR/Cas9 system, we generated cells with deactivated IFNGR1 (TC-1/dIfngr1 and TC-1/A9/dIfngr1). In tumors, IFNGR1 deactivation did not lead to PD-L1 or MHC-I reduction on tumor cells. From potential inducers, mainly IFN-α and IFN-β enhanced PD-L1 and MHC-I expression on TC-1/dIfngr1 and TC-1/A9/dIfngr1 cells in vitro. Neutralization of the IFN-α/IFN-β receptor confirmed the effect of these cytokines in vivo. Combined immunotherapy with PD-L1 blockade and DNA vaccination showed that IFNGR1 deactivation did not reduce tumor sensitivity to anti-PD-L1. Thus, the impairment of IFN-γ signaling may not be sufficient for PD-L1...Continue Reading

References

Jul 28, 2004·Immunology Letters·Pornpan Youngnak-PiboonratanakitMiyuki Azuma
Jun 28, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M Raza Zaidi, Glenn Merlino
Aug 15, 2014·Cancer Immunology Research·Kelly G PaulsonPaul Nghiem
Dec 15, 2015·Oncotarget·Grazia CarbottiSilvano Ferrini
Apr 20, 2016·JAMA : the Journal of the American Medical Association·Antoni RibasCaroline Robert
May 10, 2016·The Journal of Clinical Investigation·Janice M MehnertShridar Ganesan
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Aug 31, 2016·Nature Communications·Chia-Wei LiMien-Chie Hung
Nov 22, 2016·Cancer Cell·Seung-Oe LimMien-Chie Hung
Dec 3, 2016·Cancer Discovery·Daniel Sanghoon ShinAntoni Ribas
Jan 12, 2017·Cancer Immunology Research·Takuro NoguchiRobert D Schreiber
Feb 2, 2017·Journal of Biomedical Science·Chiou-Feng LinTsung-Ting Tsai
Feb 15, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria L AsciertoSuzanne L Topalian
Mar 18, 2017·The Journal of Experimental Medicine·Vikram R JunejaArlene H Sharpe
May 13, 2017·Cell Reports·Angel Garcia-DiazAntoni Ribas
May 17, 2017·Oncoimmunology·Jan Willem KleinovinkMarieke F Fransen
Oct 24, 2017·Frontiers in Pharmacology·Greta GarridoBelinda Sánchez-Ramírez
Oct 27, 2017·Nature Communications·Moshe Sade-FeldmanNir Hacohen
Jan 18, 2018·The Journal of Clinical Investigation·Haidong TangYang-Xin Fu
Mar 24, 2018·Science·Antoni Ribas, Jedd D Wolchok
May 29, 2018·Journal of Cancer·Hongming Zhang, Jibei Chen
Nov 21, 2018·Drugs·Anthony Markham, Sean Duggan
Nov 30, 2018·Frontiers in Pharmacology·Luca FalzoneMassimo Libra
Jan 29, 2019·Precision Clinical Medicine·Ming Liu, Fukun Guo
May 28, 2019·Life Science Alliance·Bonnie L BullockRaphael A Nemenoff
Jul 16, 2019·The Journal of Clinical Investigation·Li-Chuan ChanMien-Chie Hung
Oct 3, 2019·Cancers·Theodoulakis ChristofiApostolos Zaravinos
Oct 31, 2019·Cell Reports·Linda SchadtMaries van den Broek

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Datasets Mentioned

BETA
GM-CSF

Methods Mentioned

BETA
flow cytometry
transfection
FCS
ELISA

Software Mentioned

Graph
Prism
- Pad
FlowJo

Related Concepts

Related Feeds

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.